Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis (Q41929750)
Jump to navigation
Jump to search
scientific article published on 22 September 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis |
scientific article published on 22 September 2017 |
Statements
1 reference
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis (English)
1 reference
Kris V Kowdley
1 reference
Tarik Asselah
1 reference
Neddie Zadeikis
1 reference
Stanley Wang
1 reference
Tarek Hassanein
1 reference
Yves Horsmans
1 reference
Massimo Colombo
1 reference
Filipe Calinas
1 reference
Humberto Aguilar
1 reference
Victor de Ledinghen
1 reference
Parvez S Mantry
1 reference
Christophe Hezode
1 reference
Rui Tato Marinho
1 reference
Kosh Agarwal
1 reference
Frederik Nevens
1 reference
Magdy Elkhashab
1 reference
Jens Kort
1 reference
Ran Liu
1 reference
Teresa I Ng
1 reference
Preethi Krishnan
1 reference
Chih-Wei Lin
1 reference
Federico J Mensa
1 reference
22 September 2017
1 reference
1 reference
Identifiers
1 reference